Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma

BMC Cancer

William A. Werbel¹  Philip H. Imus²  Jacqueline M. Garonzik-Wang³  Brian J. Boyarsky³  Jake A. Ruddy³  Ross S. Greenberg³  Dorry L. Segev⁴ 

[1] Department of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA;Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA;Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA;Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA;Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA;

关键词: Multiple myeloma;    COVID-19;    SARS-CoV-2;    mRNA vaccination;    Antibody;   

DOI  :  10.1186/s12885-021-09097-5

来源: Springer

【 摘 要 】

BackgroundPatients with multiple myeloma (MM) were excluded from the original SARS-CoV-2 mRNA vaccine trials, which may influence vaccine hesitancy in this population. We prospectively characterized the safety and immunogenicity of two-dose SARS-CoV-2 mRNA vaccination in 44 patients with MM, who underwent vaccination from 12/17/2020 to 3/18/2021.ResultsRates adverse reactions were low and consistent with those documented in vaccine trials. Among those on MM therapy, 93% developed detectable anti-receptor binding domain (RBD) antibodies after dose 2, while 94% of patients not on MM therapy seroconverted.ConclusionsTwo-dose SARS-CoV-2 mRNA vaccination is mildly reactogenic and leads to high rates of seroconversion in patients with MM. These findings can provide reassurance to MM patients who are hesitant to receive SARS-CoV-2 mRNA vaccines.

【 授权许可】

CC BY